MXCT [NASD]
MaxCyte, Inc.
Index- P/E- EPS (ttm)-0.18 Insider Own10.25% Shs Outstand101.31M Perf Week34.27%
Market Cap462.05M Forward P/E- EPS next Y-0.27 Insider Trans0.00% Shs Float96.24M Perf Month19.05%
Income-16.00M PEG- EPS next Q-0.08 Inst Own86.30% Short Float2.77% Perf Quarter-23.91%
Sales39.00M P/S11.85 EPS this Y-23.80% Inst Trans2.13% Short Ratio4.09 Perf Half Y-49.03%
Book/sh2.59 P/B2.03 EPS next Y0.00% ROA-6.80% Target Price13.67 Perf Year-
Cash/sh2.80 P/C1.88 EPS next 5Y- ROE-7.40% 52W Range3.36 - 17.44 Perf YTD-48.48%
Dividend- P/FCF- EPS past 5Y-12.90% ROI-6.90% 52W High-69.90% Beta-
Dividend %- Quick Ratio16.70 Sales past 5Y22.50% Gross Margin89.70% 52W Low56.25% ATR0.37
Employees65 Current Ratio17.10 Sales Q/Q-24.20% Oper. Margin-40.90% RSI (14)64.49 Volatility10.51% 8.76%
OptionableYes Debt/Eq0.00 EPS Q/Q46.00% Profit Margin-41.20% Rel Volume1.00 Prev Close4.95
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume652.77K Price5.25
Recom1.20 SMA2024.49% SMA5011.51% SMA200-34.88% Volume647,304 Change6.06%
Oct-15-21Resumed Cowen Outperform
Aug-24-21Initiated William Blair Outperform
Aug-24-21Initiated Wedbush Outperform $36
Aug-24-21Initiated Stifel Buy $18
Aug-24-21Initiated Stephens Overweight $19
Aug-24-21Initiated Cowen Outperform
Aug-24-21Initiated BTIG Research Buy $22
Jun-23-22 03:50AM  
May-13-22 04:30PM  
09:45AM  
May-10-22 05:00AM  
May-09-22 04:05PM  
04:05PM  
May-03-22 04:05PM  
Apr-20-22 04:05PM  
Apr-15-22 09:00AM  
Apr-12-22 04:05PM  
Mar-22-22 11:30PM  
04:05PM  
Mar-15-22 03:56AM  
Mar-09-22 04:15PM  
Feb-24-22 08:00AM  
Feb-14-22 08:00AM  
Feb-11-22 05:00PM  
Feb-01-22 02:00AM  
Jan-24-22 02:30AM  
Jan-14-22 06:53AM  
Dec-17-21 04:38AM  
03:38AM  
Nov-17-21 11:37AM  
Nov-15-21 04:42AM  
Nov-12-21 08:00AM  
05:01AM  
Nov-10-21 04:00PM  
04:00PM  
Nov-03-21 09:00AM  
Oct-29-21 12:40PM  
Oct-28-21 10:00AM  
Oct-25-21 04:30PM  
Sep-17-21 08:35AM  
Sep-13-21 05:50PM  
04:05PM  
Sep-02-21 08:05AM  
Aug-09-21 02:00AM  
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOUGLAS RICHARDDirectorNov 22Buy11.1220,000222,40020,000Nov 23 07:46 AM
Holtz RonSVP and CAONov 16Option Exercise0.0439,1301,565164,381Nov 16 07:09 PM
Masoud MaherEVP and General CounselNov 16Option Exercise3.2518,56260,32618,562Nov 16 07:14 PM
Murphy Amanda LouiseChief Financial OfficerNov 16Option Exercise4.4237,306164,89337,306Nov 16 07:12 PM
Doerfler DouglasPresident and CEONov 16Option Exercise0.0474,8902,996408,087Nov 16 07:08 PM
Ross Thomas M.EVP, Global SalesNov 16Option Exercise0.8431,16326,17731,163Nov 16 07:10 PM
Ross Thomas M.EVP, Global SalesNov 16Sale12.0831,163376,4490Nov 16 07:10 PM
Doerfler DouglasPresident and CEONov 16Sale12.0874,890904,671333,197Nov 16 07:08 PM
Holtz RonSVP and CAONov 16Sale12.0839,130472,690125,251Nov 16 07:09 PM
Murphy Amanda LouiseChief Financial OfficerNov 16Sale12.0837,306450,6560Nov 16 07:12 PM
Masoud MaherEVP and General CounselNov 16Sale12.0818,562224,2290Nov 16 07:14 PM
Holtz RonSVP and CAONov 15Option Exercise0.0464,3852,575189,636Nov 16 07:09 PM
Masoud MaherEVP and General CounselNov 15Option Exercise2.3330,71671,42230,716Nov 16 07:14 PM
Murphy Amanda LouiseChief Financial OfficerNov 15Option Exercise4.4261,591272,23261,591Nov 16 07:12 PM
Doerfler DouglasPresident and CEONov 15Option Exercise0.04123,2634,931456,460Nov 16 07:08 PM
Ross Thomas M.EVP, Global SalesNov 15Option Exercise0.8451,35243,13651,352Nov 16 07:10 PM
Ross Thomas M.EVP, Global SalesNov 15Sale12.1651,352624,4400Nov 16 07:10 PM
Doerfler DouglasPresident and CEONov 15Sale12.16123,2631,498,878333,197Nov 16 07:08 PM
Murphy Amanda LouiseChief Financial OfficerNov 15Sale12.1661,591748,9470Nov 16 07:12 PM
Masoud MaherEVP and General CounselNov 15Sale12.1630,716373,5070Nov 16 07:14 PM
Holtz RonSVP and CAONov 15Sale12.1664,385782,922125,251Nov 16 07:09 PM
Holtz RonSVP and CAONov 12Option Exercise0.0421,485859171,736Nov 16 07:09 PM
Masoud MaherEVP and General CounselNov 12Option Exercise2.0825,72253,50225,722Nov 16 07:14 PM
Ross Thomas M.EVP, Global SalesNov 12Option Exercise0.8442,59035,77642,590Nov 16 07:10 PM
Doerfler DouglasPresident and CEONov 12Option Exercise0.041,84774435,044Nov 16 07:08 PM
Murphy Amanda LouiseChief Financial OfficerNov 12Option Exercise4.4251,103225,87551,103Nov 16 07:12 PM
Murphy Amanda LouiseChief Financial OfficerNov 12Sale12.6651,103646,9640Nov 16 07:12 PM
Ross Thomas M.EVP, Global SalesNov 12Sale12.6642,590539,1890Nov 16 07:10 PM
Doerfler DouglasPresident and CEONov 12Sale12.66101,8471,289,383333,197Nov 16 07:08 PM
Holtz RonSVP and CAONov 12Sale12.6546,485588,035125,251Nov 16 07:09 PM
Masoud MaherEVP and General CounselNov 12Sale12.6625,722325,6410Nov 16 07:14 PM